Clinical Study on Thymus-Kidney Transplantation From Neonatal Donors for the Induction of Immune … (NCT06715865) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Clinical Study on Thymus-Kidney Transplantation From Neonatal Donors for the Induction of Immune Tolerance
China10 participantsStarted 2025-01
Plain-language summary
Thymus transplantation for the induction of immune tolerance in kidney transplantation: This study aims to understand how thymus transplantation can induce immune tolerance in recipients of allogeneic kidney transplants to achieve the discontinuation of immunosuppressive therapy. It will evaluate the safety of thymus transplantation, explore the functional output of thymus tissue, investigate the optimal timing for withdrawal of immunosuppressants, and identify key indicators for the reconstruction of immune suppression capacity.
Who can participate
Age range18 Years – 65 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Recipients of both thymus and kidney transplants from the same donor.
✓. Age between 18 and 65 years.
✓. Non-solid organ combination transplant recipients (including heart-kidney or liver-kidney transplants, except thymus).
✓. ABO blood type compatibility with the donor.
✓. Negative donor-specific antibody (DSA).
✓. Negative lymphocyte crossmatch (CDC).
✓. Normal cardiac function (confirmed through ECG and echocardiograms).
✓. Normal liver function.
Exclusion criteria
✕. Clinically significant genital or urinary tract dysfunction.
✕. Underlying kidney diseases with a high risk of recurrence in the transplanted kidney, including: